Download PDF

1. Company Snapshot

1.a. Company Description

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation.The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression.It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease.


The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease.It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F.Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine.


The company was formerly known as Sangamo BioSciences, Inc.and changed its name to Sangamo Therapeutics, Inc.in January 2017.


Sangamo Therapeutics, Inc.was incorporated in 1995 and is headquartered in Brisbane, California.

Show Full description

1.b. Last Insights on SGMO

Sangamo Therapeutics' recent performance was negatively impacted by a Q4 loss of $0.11 per share, missing revenue estimates. The company's earnings release highlighted a decline in revenue, which was partly offset by a strong pipeline of genomic medicines. The ongoing investigation by Pomerantz Law Firm on behalf of investors, citing potential claims against the company, also contributed to the negative sentiment. Furthermore, the lack of significant updates on the Fabry Disease gene therapy program, despite the expected release of phase 1/2 STAAR study data in 1H 2025, may have dampened investor enthusiasm.

1.c. Company Highlights

2. Sangamo's 2025 Surge: Fabry & Neurology

Revenue for 2025 surged 92.5%, reaching $42.3 million, a stark contrast to the prior year’s $22.6 million. Operating margin tightened to –18.4%, reflecting high R&D and regulatory costs. Earnings per share fell to –$0.11 versus the consensus estimate of $0.01, underscoring the company’s heavy investment in clinical development. Staff noted the company raised $130 million in non‑dilutive funding and equity, bolstering its cash position. Valuation metrics highlight a P/S ratio of 2.74 and an EV/EBITDA of –1.12, indicating the market’s cautious stance amid ongoing clinical milestones.

Publication Date: Apr -19

📋 Highlights
  • Positive STAAR Study Results: Demonstrated a positive mean annualized eGFR slope at 52 weeks across all patients in the registrational trial for Fabry disease.
  • BLA Submission Progress: Rolling biologics license agreement (BLA) submission for ST-920 is ongoing, with a companion diagnostic accepted by the FDA CDRH for premarket approval.
  • $130M in Funding Raised: Secured over $130 million since 2025 start via non-dilutive fees, milestones, and equity financing to support operations and pipeline development.
  • Neurology Pipeline Expansion: Activated six clinical sites for the Phase I/II STAND study in chronic neuropathic pain and received Fast Track designation for ST-503 in small fiber neuropathy.
  • Cash Runway Challenges: Prioritizing long-term capital solutions while pursuing a commercial partner for Fabry to address liquidity and funding constraints.

Revenue Outlook

Projected 2026 revenue is expected to climb by 18.7%, driven by anticipated Phase II data from the STAAR trial and early commercial interest in ST‑920. The company’s focus on securing a commercial partner for Fabry is central to realizing these top‑line gains, with multiple biotech firms reportedly engaged in partnership discussions.

Pipeline Highlights

The registrational STAAR study in Fabry disease reported a positive mean annualized eGFR slope at 52 weeks, supporting the efficacy of ST‑920. Concurrently, the Phase I/II STAND study in chronic neuropathic pain expanded to six sites, marking a pivotal shift to a clinical‑stage neurology platform. Fast Track designation for ST‑503 in small fiber neuropathy further diversifies the therapeutic portfolio.

Cash Position

Cash runway remains a critical concern; the company has not yet secured a long‑term financing solution. Despite $130 million in recent capital raises, free cash flow yield stands at –89.65%, and the net debt/EBITDA ratio is –0.06, reflecting an almost debt‑free stance but limited liquidity for sustained R&D spending.

Strategic Partnerships

Securing a commercial partner for Fabry remains the top priority, with ongoing negotiations involving multiple potential collaborators. The company’s BLA submission to the FDA for ST‑920 and the companion diagnostic’s FDA CDRH premarket approval submission are key milestones that could unlock partnership opportunities and accelerate market entry.

Valuation Snapshot

Current valuation reflects a P/E ratio of –0.72 and a P/B ratio of –6.2, underscoring the market’s discounting of the company’s earnings potential due to high R&D costs and uncertain commercial prospects. The P/S ratio of 2.74 suggests that, despite negative earnings, the market still values the company’s revenue generation capacity at a modest premium, while the negative EV/EBITDA signals that profitability is not yet realized.

3. NewsRoom

Card image cap

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

Apr -30

Source: globenewswire.com

Card image cap

Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

Apr -29

Source: globenewswire.com

Card image cap

Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript

Mar -30

Source: seekingalpha.com

Card image cap

Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

Mar -30

Source: globenewswire.com

Card image cap

Sangamo Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Mar -30

Source: feeds.benzinga.com

Card image cap

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

Mar -19

Source: globenewswire.com

Card image cap

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026

Feb -03

Source: globenewswire.com

Card image cap

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering

Feb -03

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.98%)

6. Segments

Zinc Finger Protein

Expected Growth: 9.98%

Sangamo Therapeutics' Zinc Finger Protein growth is driven by increasing adoption in gene editing, rising demand for novel cancer therapies, and strategic partnerships. The 9.98% growth rate is also fueled by advancements in gene regulation, expanding pipeline of therapeutic candidates, and growing investments in gene therapy research.

7. Detailed Products

ZFN Gene Editing

A precise and efficient gene editing technology that enables the modification of genes in living cells.

ZFP Therapeutic Proteins

A platform for the development of therapeutic proteins that can be used to treat a range of diseases, including cancer and genetic disorders.

Cell and Gene Therapy

A platform for the development of cell and gene therapies that can be used to treat a range of diseases, including cancer and genetic disorders.

Genome Regulation

A platform for the development of therapies that can be used to regulate gene expression and treat a range of diseases.

8. Sangamo Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Sangamo Therapeutics, Inc. operates in a highly competitive industry, but the threat of substitutes is mitigated by the company's focus on gene therapy and gene editing, which is a niche area with limited substitutes.

Bargaining Power Of Customers

Sangamo Therapeutics, Inc. has a diverse customer base, including pharmaceutical and biotechnology companies, which reduces the bargaining power of individual customers.

Bargaining Power Of Suppliers

Sangamo Therapeutics, Inc. relies on a few key suppliers for raw materials and equipment, which gives them some bargaining power, but the company's strong relationships with suppliers mitigate this risk.

Threat Of New Entrants

The gene therapy and gene editing industry is rapidly evolving, and new entrants with innovative technologies could potentially disrupt Sangamo Therapeutics, Inc.'s market position.

Intensity Of Rivalry

The gene therapy and gene editing industry is highly competitive, with several established players and new entrants vying for market share, which increases the intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 31.49%
Debt Cost 3.95%
Equity Weight 68.51%
Equity Cost 10.90%
WACC 8.71%
Leverage 45.97%

11. Quality Control: Sangamo Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Cara Therapeutics

A-Score: 4.1/10

Value: 7.5

Growth: 1.1

Quality: 3.9

Yield: 0.0

Momentum: 10.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Eyenovia

A-Score: 3.7/10

Value: 8.0

Growth: 4.7

Quality: 3.3

Yield: 0.0

Momentum: 6.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Ikena Oncology

A-Score: 3.3/10

Value: 6.2

Growth: 1.8

Quality: 4.1

Yield: 0.0

Momentum: 3.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
HCW Biologics

A-Score: 2.9/10

Value: 8.2

Growth: 4.2

Quality: 4.9

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Orchestra BioMed

A-Score: 2.6/10

Value: 6.0

Growth: 2.9

Quality: 3.6

Yield: 0.0

Momentum: 2.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Sangamo Therapeutics

A-Score: 2.6/10

Value: 7.4

Growth: 3.3

Quality: 4.1

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.13$

Current Price

0.14$

Potential

-0.00%

Expected Cash-Flows